

1 We would like to thank all reviewers for their valuable feedback which has helped us improve the paper!

2 **Reviewer 1: ■ Dataset descriptions:** Please note that Appendix I contains details about the datasets used in terms of
3 patient features, possible interpretations of treatments and of patient outcomes. We also provide links to the publicly
4 available datasets. Upon acceptance, we will release the code for the model and for the semi-synthetic data generation.

5 **Reviewer 2: ■ Novelty:** Our method only draws inspiration from [6] in terms of using a GAN framework to learn
6 counterfactual outcomes. Nevertheless, to handle continuous interventions, we propose a novel hierarchical discriminator
7 architecture. We also provide theoretical results, which are lacking from [6] to show that the proposed GAN framework
8 can indeed learn the distribution of the counterfactual outcomes. Finally, we introduce a new semi-synthetic data
9 simulation that can be used to benchmark causal inference methods for estimating the effects of continuous interventions.

10 **■ Sample efficiency:** Our remark regarding sample efficiency was
11 perhaps a bit offhand. Experimentally, we showed that SCIGAN works
12 for a few thousand samples (using the MIMIC dataset with 1920 training
13 samples). We had not investigated how SCIGAN performs below this
14 number. We have now performed a further experiment to evaluate model
15 performance in terms of sample efficiency. For the MIMIC dataset, in
16 Table 1 we report evaluation metrics for training SCIGAN with different
17 number of training samples N and evaluating on the same test set.

	$\sqrt{\text{MISE}}$	$\sqrt{\text{DPE}}$	$\sqrt{\text{PE}}$
$N = 100$	31.12 ± 63.39	7.72 ± 2.57	18.94 ± 29.07
$N = 500$	13.36 ± 10.46	4.07 ± 1.92	2.63 ± 0.94
$N = 1000$	3.80 ± 1.04	2.46 ± 1.75	1.03 ± 1.13
$N = 1500$	2.95 ± 0.37	0.70 ± 0.17	0.63 ± 0.12
$N = 1920$	2.09 ± 0.12	0.51 ± 0.05	0.32 ± 0.05

Table 1: Sample efficiency analysis for MIMIC. Metrics are reported as Mean \pm Std.

18 **■ PCA for GPS model:** PCA is only used for the GPS model for TCGA and News datasets, which contain a large
19 number of features, to reduce computational complexity. Since GPS is a linear method, using PCA as a pre-processing
20 step helps avoid problems with co-linear features. We used a publicly available implementation for GPS based on
21 the `causaldrf` package in R. After re-running GPS without PCA on News we obtained similar results to the ones in
22 Table 3 in the paper: 6.03 ± 0.01 ($\sqrt{\text{MISE}}$), 6.83 ± 0.01 ($\sqrt{\text{DPE}}$) and 22.56 ± 0.03 ($\sqrt{\text{PE}}$). **■ Code and data:** We
23 will release the code for the model and semi-synthetic data generation upon acceptance. **■ Calibration:** We did not
24 consider calibration - though it would certainly be an interesting future research direction. We would note, though,
25 that [R1] is not about improving the generator but rather gleaning a useful discriminator from the training procedure
26 (which would normally result in a degenerate discriminator), which could be used at test-time to evaluate the generated
27 response-curves. We will add discussion about this in the conclusion. **■ Hierarchical discriminator:** The term
28 hierarchical refers to the fact that there are 2 levels to our discrimination procedure - (1) determine the factual treatment;
29 (2) determine the factual dosage given the factual treatment. In contrast with the term ensemble which would typically
30 refer to several models performing the same task, we have different models performing different tasks. **■ Permutation
31 invariance and equivariance:** We use permutation invariance and equivariance because we are fundamentally dealing
32 with dose-response curves, which are themselves functions. To treat these as functions, we treat them as sets of points
33 of the form (input, output). For this reason we use permutation invariance and equivariance - so that the networks act as
34 functions on sets (rather than functions on vectors which would be the case without the in-/equi-variance).

35 **Reviewer 3: ■ Presentation and notation:** Please note that the problem we are aiming to solve requires complex
36 notation due to the fact that we are handling treatments with continuous dosage. Moreover, our choice of architecture in
37 terms of the hierarchical discriminator also needs complex notation. Unfortunately, we do not feel that the notation
38 can be simplified much. Appendix B contains a table for all of our notation and we will work further to improve the
39 presentation and notation in the revised manuscript. **■ Details in appendices:** Due to the page limit for the conference,
40 it was not possible to add all of the details in the main paper. We have tried to keep as much information as possible in
41 the main paper, which involved many tough decisions about what was best placed in the main paper and what could
42 be placed in the appendix. **■ Stopping criteria for the GAN network:** For all experiments with SCIGAN, we used
43 5000 training iterations for the GAN network. This number of training iterations was chosen to ensure convergence
44 of the generator loss, discriminator loss, as well as of the supervised loss. We will include details about the number
45 of training iterations used in the paper. **■ Issues with GAN training:** We have not encountered gradient vanishing
46 problems when training our SCIGAN. It is not clear to us how the problem of mode collapse would even present itself
47 in this setting as we are not discriminating between entirely real and entirely fake samples. **■ Evaluation on real data
48 and real-world applicability:** In real datasets, we only observe the outcome for the patient for a specific setting of the
49 treatment and the dosage. The counterfactual outcomes, i.e. the patient outcomes under different possible interventions,
50 cannot be observed. This is why it is not possible to use real data to evaluate how well the methods can estimate the
51 entire dose-response curve for each patient. However, this does not mean that this method cannot be deployed in real
52 world environments. In this regard, the problem is no different to the very well studied problem of treatment effect
53 estimation for a binary/categorical treatment [6, 16, R2] for which there is a *wealth* of existing literature containing
54 many examples of real-world applications. Evaluation on semi-synthetic data is standard for causal inference methods.

55 [R1] Dai, Zihang, et al. "Calibrating energy-based generative adversarial networks." preprint arXiv:1702.01691 (2017).
56 [R2] Jennifer L. Hill, "Bayesian nonparametric modeling for causal inference." JCGS, 2011